Ibandronate Sodium Catalog No.:M8787-2 7(8):1447-52

7(8):1447-52

Wnt-C59 was used to dose mice orally at 5-10 mg/kg once per day or 5 mg/kg twice per day

58 μM on HCT116 cells

and is 18- and 2-fold less potent than (-)-nicotine at human α4β2 and a7 nAChR

PubMed PMID: 19122279

Ibandronate Sodium Catalog No.:M8787-2 7(8):1447-52Ibandronate sodium is a potent bisphosphonate drug developed by Hoffman La Roche and used in the prevention and treatment of osteoporosis and metastasis associated skeletal fractures in people with cancer. It may also be used to treat hypercalcemia (elevated blood calcium levels). Ibandronate is indicated for the treatment and prevention of osteoporosis in post menopausal women. In May 2003, the U. S. Food and Drug Administration (FDA) approved